Receive The Newest Study Notifications

ATLANTA -- A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a...

A brain-cancer vaccine more than 20 years in the making suspends cancer growth in patients enrolled in early-stage trial. Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a...

-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout -Strengthened management and clinical teams with the appointments of Elona Kogan, J.D. as General Counsel & Corporate...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the...

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. A phase I clinical trial that set out to assess the safety of a new combination...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme)...

Mareana today announced that it has been included in Gartner's January 17, 2019 artificial intelligence (AI) research note, Life Sciences CIOs, Accelerate Clinical Development with New Applications of Artificial Intelligence, written by analysts Jeff Smith and Michael...

Proteon Therapeutics, based in Waltham, Mass., announced that its PATENCY-2 Phase III clinical trial of vonapanitase in chronic kidney disease (CKD) failed to meet its co-primary endpoints. Vonapanitase was being evaluated in patients with CKD undergoing creation of a...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a poster with data from an ongoing clinical trial evaluating the...

-First patient enrolled in COMPARE trial evaluating efficacy and safety of SEL-212 v. KRYSTEXXA® in patients with chronic refractory gout -Strengthened management and clinical teams with the appointments of Elona Kogan, J.D. as General Counsel & Corporate...

Eisai Co., Ltd. announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609)...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem's...

400 mg dose reached statistical significance compared to placebo, consistent with previous Phase III studies: • Change versus baseline in ADHD Rating Scale 5, p-value = 0.0082 • Effect size of 0.66 • CGI-I secondary endpoint, p-value = 0.0051...

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced three presentations of updated clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2019, to be held March 29-April...

Phase Ib First-in-Human study in ß -Thalassemia and MDS patients, with the first patient expected to enter the clinic in Q3 2019 Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA...

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present next week at the Influenza Vaccines for the Worldconference in Edinburgh, Scotland, UK. Joshua Phillipson, BiondVax's Head of...

Blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E, met its primary and all secondary endpoints, supporting the long-term safety and efficacy profile of TRC101 Patients treated with TRC101 showed a significant reduction in all-cause mortality...

LUND, Sweden, March 26, 2019 /PRNewswire/ -- Hansa Biopharma AB(NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it received Clinical Trial Application and Ethics Committee approvals for the...

Lambert Initiative facilitating supply for clinical trial A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated...

New rules well balanced, focused on patient rights, safety and well-being Welcoming the New Drugs and Clinical Trial Rules, 2019 which were notified by the Ministry of Health & Family Welfare and made public on March 25th, the Indian Society for Clinical Research...